Characteristics of study participants
| Characteristic | SLE/CYC− (n=68) | SLE/CYC+ (n=11) | Comparison (n=83) |
| AMH in ng/mL (mean (SD)) | 2.99 (3.17) | 1.17 (0.63) | 3.26 (3.15) |
| Age at interview (n (%)), years | |||
| 22–30 | 25 (36.8) | 6 (54.6) | 6 (7.2) |
| 31–34 | 9 (13.2) | 2 (18.2) | 20 (24.1) |
| 35–37 | 15 (22.1) | 3 (27.3) | 29 (34.9) |
| 38–40 | 19 (27.9) | 0 (0.0) | 28 (33.7) |
| Age at SLE diagnosis (n (%)), years | |||
| 18–20 | 17 (25.0) | 3 (27.3) | |
| 21–25 | 23 (33.8) | 7 (63.6) | |
| 26–30 | 14 (20.6) | 1 (9.1) | |
| 31–35 | 14 (20.6) | 0 (0.0) | |
| Body mass index (n (%)) | |||
| Underweight (<18.5 kg/m2) | 3 (4.4) | 0 (0.0) | 1 (1.2) |
| Normal weight (18.5–<25 kg/m2) | 16 (23.5) | 7 (63.6) | 17 (20.5) |
| Overweight (25–<30 kg/m2) | 19 (27.9) | 2 (18.2) | 31 (37.4) |
| Obese (≥30 kg/m2) | 30 (44.1) | 2 (18.2) | 34 (41.0) |
| Hormonal contraception in previous 12 months (n (%)) | 14 (20.6) | 2 (18.2) | 24 (28.9) |
| Experienced menopause* (n (%)) | 3 (4.4) | 0 (0.0) | 0 (0.0) |
*Amenorrhoea for 12 months or longer without resumption of menses.
AMH, anti-Müllerian hormone; CYC, cyclophosphamide.